NCT01039454View on ClinicalTrials.gov

Effects of the D3 Antagonist GSK598809 on Food Reward and Reinforcement

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 18, 2008

Primary Completion Date

April 26, 2010

Study Completion Date

April 26, 2010

Conditions
Substance Dependence
Interventions
DRUG

GSK598809 Capsules

GSK598809 is being developed for the treatment of substance dependence and potentially other impulse control disorders.

DRUG

GSK598809 Placebo Capsules

Treatment of substance dependence and potentially other impulse control disorders.

Trial Locations (2)

CB2 0QQ

GSK Investigational Site, Cambridge

NW10 7EW

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY